DK0914122T3 - Fremgangsmåde til behandling og forebyggelse af neurodegenerative sygdomme ved administrering af en thiazolidinon - Google Patents

Fremgangsmåde til behandling og forebyggelse af neurodegenerative sygdomme ved administrering af en thiazolidinon

Info

Publication number
DK0914122T3
DK0914122T3 DK97933264T DK97933264T DK0914122T3 DK 0914122 T3 DK0914122 T3 DK 0914122T3 DK 97933264 T DK97933264 T DK 97933264T DK 97933264 T DK97933264 T DK 97933264T DK 0914122 T3 DK0914122 T3 DK 0914122T3
Authority
DK
Denmark
Prior art keywords
thiazolidinone
pct
administration
treating
neurodegenerative diseases
Prior art date
Application number
DK97933264T
Other languages
Danish (da)
English (en)
Inventor
Richard Thomas Carroll
Richard Dennis Dyer
Lillian Jane Robichaud
Brenda De Rae Shivers
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of DK0914122T3 publication Critical patent/DK0914122T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
DK97933264T 1996-07-11 1997-07-01 Fremgangsmåde til behandling og forebyggelse af neurodegenerative sygdomme ved administrering af en thiazolidinon DK0914122T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2157196P 1996-07-11 1996-07-11
PCT/US1997/011586 WO1998002160A1 (en) 1996-07-11 1997-07-01 Method for treating and preventing neurodegenerative disorders by administering a thiazolidinone

Publications (1)

Publication Number Publication Date
DK0914122T3 true DK0914122T3 (da) 2003-12-22

Family

ID=21804973

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97933264T DK0914122T3 (da) 1996-07-11 1997-07-01 Fremgangsmåde til behandling og forebyggelse af neurodegenerative sygdomme ved administrering af en thiazolidinon

Country Status (22)

Country Link
US (1) US5912259A (de)
EP (1) EP0914122B1 (de)
JP (1) JP2001508028A (de)
KR (1) KR20000023683A (de)
CN (1) CN1145481C (de)
AT (1) ATE250416T1 (de)
AU (1) AU726664B2 (de)
BR (1) BR9710467A (de)
CA (1) CA2255073A1 (de)
CO (1) CO4940509A1 (de)
DE (1) DE69725147T2 (de)
DK (1) DK0914122T3 (de)
ES (1) ES2205247T3 (de)
HR (1) HRP970362A2 (de)
IL (1) IL127487A (de)
NO (1) NO990076D0 (de)
NZ (1) NZ332763A (de)
PL (1) PL331049A1 (de)
PT (1) PT914122E (de)
TR (1) TR199900040T2 (de)
WO (1) WO1998002160A1 (de)
ZA (1) ZA976142B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003104423A2 (en) * 2002-06-11 2003-12-18 Roy Ogle Meningeal-derived stem cells
WO2009137109A1 (en) * 2008-05-08 2009-11-12 Rutgers, The State University Endorphin therapy compositions and methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT83152B (pt) * 1985-08-09 1989-03-30 Lilly Co Eli Processo para a preparacao de compostos di-t-butilfenoicos
DE69027472T2 (de) * 1989-04-07 1996-12-05 Lilly Co Eli Arylsubstituierte Rhodaninderivate
US5143928A (en) * 1990-03-27 1992-09-01 Warner-Lambert Company 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents
US5192753A (en) * 1991-04-23 1993-03-09 Mcgeer Patrick L Anti-rheumatoid arthritic drugs in the treatment of dementia
CZ181493A3 (en) * 1992-09-10 1994-03-16 Lilly Co Eli The use of rhodanine derivative for the preparation of a pharmaceutical composition reducing level of sugar in blood and for treating alzheimer's disease
EP0722729A3 (de) * 1995-01-23 1997-11-26 Eli Lilly And Company Aryl-substituierte Rhodaninen zur Behandlung multipler Sklerose
ATE301457T1 (de) * 1995-06-12 2005-08-15 Searle & Co Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor

Also Published As

Publication number Publication date
ATE250416T1 (de) 2003-10-15
DE69725147D1 (de) 2003-10-30
ZA976142B (en) 1998-02-02
KR20000023683A (ko) 2000-04-25
AU3649197A (en) 1998-02-09
HK1020533A1 (en) 2000-05-12
IL127487A0 (en) 1999-10-28
NZ332763A (en) 2000-07-28
PT914122E (pt) 2003-12-31
NO990076L (no) 1999-01-08
CN1223582A (zh) 1999-07-21
JP2001508028A (ja) 2001-06-19
CO4940509A1 (es) 2000-07-24
PL331049A1 (en) 1999-06-21
EP0914122A1 (de) 1999-05-12
WO1998002160A1 (en) 1998-01-22
CA2255073A1 (en) 1998-01-22
CN1145481C (zh) 2004-04-14
BR9710467A (pt) 1999-08-17
US5912259A (en) 1999-06-15
TR199900040T2 (xx) 1999-04-21
IL127487A (en) 2002-04-21
HRP970362A2 (en) 1998-04-30
DE69725147T2 (de) 2004-07-22
EP0914122B1 (de) 2003-09-24
AU726664B2 (en) 2000-11-16
NO990076D0 (no) 1999-01-08
ES2205247T3 (es) 2004-05-01

Similar Documents

Publication Publication Date Title
DE69709070D1 (de) Verbrückte zyklische aminosäuren als pharmazeutische mittel
IS4819A (is) Nýstárlegar staðgengnar hringamínósýrur notaðar til lyfjagerðar
DE69712877D1 (de) Zyklischaminosäure als pharmazeutische mittel
DK1014996T3 (da) Præparater indeholdende saccharid til behandling af Alzheimers sygdom og andre amyloidoser
MY132529A (en) Paroxetine hydrochloride anhydrate
DK1293207T3 (da) Anvendelse af ritonavir (ABT-538) til forbedring af farmokokinetikken af lægemidler, som metaboliseres af cytochrome P450 i en fremgangsmåde til at behandle AIDS
ATE193442T1 (de) 3,4-diarylchromane zur behandlung von dermatitis
AU4673300A (en) Amino heterocycles useful as pharmaceutical agents
ATE326965T1 (de) Pharmazeutische zusammensetzung zur behandlung von autoimmunkrankheiten
NO990076L (no) FremgangsmÕte for behandling og forhundring av nevrodegenerative tilstander ved administrasjon av tiazolidinon
SE9302218D0 (sv) New use
EP1447090B8 (de) Verwendung von Hyaluronidase zur Prophylaxe und Behandlung von Herz-Kreislauf-Erkrankungen
WO2003004046A3 (en) Use of xaa-pro peptidases for the treatment of substance p-related disorders
DE69421705D1 (de) Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen
SE9501773D0 (sv) New use